drugset / Trial / NCT03803553
Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
This research study is comparing two standard of care treatment options based on blood test results for participants who have metastatic colon cancer. The names of the potential treatments involved in this study are: * Active surveillance * FOLFIRI treatment * Nivolumab treatment * Encorafenib/Binimetinib/Cetuximab treatment * Trastuzumab + Pertuzumab
Timeline
- Start
- 2020-04-16
- Primary completion
- 2026-12
- Completion
- 2027-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Binimetinib | Small molecule | — | Oral |
| Subject | Cetuximab | Monoclonal antibody | — | Intravenous |
| Subject | Encorafenib | Small molecule | — | Oral |
| Subject | Irinotecan | Small molecule | — | Intravenous |
| Subject | Leucovorin | Small molecule | — | Intravenous |
| Subject | Nivolumab | Monoclonal antibody | — | Intravenous |
| Subject | Pertuzumab | Monoclonal antibody | — | — |
| Subject | Trastuzumab | Monoclonal antibody | — | Intravenous |
| Subject | fluorouracil | Small molecule | — | Intravenous |